

5/10/2024
Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609
AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Aquestive Therapeutics, Inc. is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on 4/29/2024. The new product being launched is:

- NDC 10094030502: Libervant (diazepam) Buccal Film, 5 MG, 2 Each, Unit-of-Use, Box
- NDC 10094030702: Libervant (diazepam) Buccal Film, 7.5 MG, 2 Each, Unit-of-Use, Box
- NDC 10094031002: Libervant (diazepam) Buccal Film, 10 MG, 2 Each, Unit-of-Use, Box
- NDC 10094031202: Libervant (diazepam) Buccal Film, 12 MG, 2 Each, Unit-of-Use, Box
- NDC 10094031502: Libervant (diazepam) Buccal Film, 15 MG, 2 Each, Unit-of-Use, Box

Sincerely,

Jean Frydman

Jean Frydman
VP Associate General Counsel & Corporate Compliance
Legal Department of Aquestive